A comparison of ligand based virtual screening methods and application to corticotropin releasing factor 1 receptor

Journal of Molecular Graphics and Modelling

Volumn 27, Issue 8, 2009, Pages 860-870

  Tresadern, Gary ^a   Bemporad, Daniele ^b   Howe, Trevor ^b  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Corticotropin releasing factor; CRF1; CRH1; Ligand based virtual screening; Scaffold hopping

Indexed keywords

ACTIVE COMPOUNDS; CHEMICAL ARCHITECTURE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN-RELEASING FACTORS; CRF1; CRH1; VIRTUAL SCREENING;

ELECTROSTATICS; LIGANDS; THREE DIMENSIONAL;

SCAFFOLDS;

CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; LIGAND;

ARTICLE; DRUG CONFORMATION; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; HYDROPHOBICITY; INTERMETHOD COMPARISON; PHARMACOPHORE; PRIORITY JOURNAL; STEREOSPECIFICITY;

AMINOPYRIDINES; COMPUTER SIMULATION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDINES; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 67249096968     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2009.01.003     Document Type: Article

References (49)

1. Steckler T., and Dautzenberg F.M. Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-an update. CNS Neurol. Dis. Drug Targets 5 (2006) 147-165
2. Owens M.J., and Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43 (1991) 425-473
3. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., and Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226 (1984) 1342-1344
4. Holsboer F., Von Bardeleben U., Gerken A., Stalla G.K., and Muller O.A. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. 311 (1984) 1127
5. Wynn P.C., Harwood J.P., Catt K.J., and Aguilera G. Corticotropin-releasing factor (CRF) induces desensitization of the rat pituitary CRF receptor-adenylate cyclase complex. Endocrinology 122 (1988) 351-358
6. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., and De Souza E.B. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 17 (1996) 166-172
7. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., and Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiat. Res. 34 (2000) 171-181
8. Bale T.L., and Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 525-557
9. Mesleh M.F., Shirley W.A., Heise C.E., Ling N., Maki R.A., and Laura R.P. NMR structural characterization of a minimal peptide antagonist bound to the extracellular domain of the corticotropin-releasing factor 1 receptor. J. Biol. Chem. 282 (2007) 6338-6346
10. Liaw C.W., Grigoriadis D.E., Lovenberg T.W., De Souza E.B., and Maki R.A. Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol. Endocrinol. 11 (1997) 980-985
11. M.E. Abreu, W. Rzeszotarski, D.J. Kyle, R.L. Elliot, Corticotropin releasing factor antagonist compounds. Patent 1991, Nova Pharmaceutical, US5063245.
12. M. Lanier, J.P. Williams, Small molecule corticotropin-releasing factor antagonists. Expert Opin. Ther. Patents 2002, 12, 1619-1630.
13. Keller P.A., Elfick L., Garner J., Morgan J., and McCluskey A. Corticotropin releasing hormone: therapeutic implications and medicinal chemistry developments. Bioorg. Med. Chem. 8 (2000) 1213-1223
14. Chen Y.L., Mansbach R.S., Winter S.M., Brooks E., Collins J., Corman M.L., Dunaiskis A.R., Faraci W.S., Gallaschun R.J., Schmidt A., and Schulz D.W. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor 1 receptor antagonist. J. Med. Chem. 40 (1997) 1749-1754
15. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., Licinio J., Wong M.L., Chrousos G.P., Webster E., and Gold P.W. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140 (1999) 79-86
16. Chen C., Wilcoxen K.M., Huang C.Q., Xie Y.F., McCarthy J.R., Webb T.R., Zhu Y.F., Saunders J., Liu X.J., Chen T.K., Bozigian H., and Grigoriadis D.E. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo [1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J. Med. Chem. 47 (2004) 4787-4798
17. Chaki S., Nakazato A., Kennis L., Nakamura M., Mackie C., Sugiura M., Vinken P., Ashton D., Langlois X., and Steckler T. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur. J. Pharma. 485 (2004) 145-158
18. Chen Y.L., Braselton J., Forman J., Gallaschun R.J., Mansbach R., Schmidt A.W., Seeger T.F., Sprouse J.S., David F., Winston E., and Schulz D.W. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists. J. Med. Chem. 51 (2008) 1377-1384
19. Chen Y.L., Obach R.S., Braselton J., Corman M.L., Forman J., Freeman J., Gallaschun R.J., Mansbach R., Schmidt A.W., Sprouse J.S., Tingley I.I.I., Winston E., and Schulz D.W. 2-Aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J. Med. Chem. 51 (2008) 1385-1392
20. Hert J., Willett P., Wilton D.J., Acklin P., Azzaoui K., Jacoby E., and Schuffenhauer A. New methods for ligand-based virtual screening: use of data fusion and machine learning to enhance the effectiveness of similarity searching. J. Chem. Inf. Model. 46 (2006) 462-470
21. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today 11 (2006) 580-594
22. Cramer R.D., Poss M.A., Hermsmeier M.A., Caulfield T.J., Kowala M.C., and Valentine M.T. Prospective identification of biologically active structures by topomer shape similarity searching. J. Med. Chem. 42 (1999) 3919-3933
23. Hou T.J., and Xu X.J. Recent development and application of virtual screening in drug discovery: an overview. Curr. Pharma. Des. 10 (2004) 1011-1033
24. Stahura F.L., and Bajorath M. New methodologies for ligand-based virtual screening. Curr. Pharma. Des. 11 (2005) 1189-1202
25. Pozzan A. Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr. Pharma. Des. 12 (2006) 2099-2110
26. Livingstone D.J. The characterization of chemical structures using molecular properties. A survey. J. Chem. Inf. Comp. Sci. 40 (2000) 195-209
27. Sheridan R.P., and Kearsley S.K. Why do we need so many chemical similarity search methods?. Drug Discov. Today 7 (2002) 903-911
28. SciTegic, Accelrys Inc. 10188 Telesis Court, Suite 100, San Diego, CA 92121.
29. Rarey M., and Dixon J.S. Feature trees: a new molecular similarity measure based on tree matching. J. Comput.-Aided Mol. Des. 12 (1998) 471-490
30. Cramer R.D., Jilek R.J., and Andrews K.M. dbtop: toporner similarity searching of conventional structure databases. J. Mol. Graphics Model. 20 (2002) 447-462
31. Grant J.A., Gallardo M.A., and Pickup B.T. A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape. J. Comp. Chem. 17 (1996) 1653-1666
32. Rush T.S., Grant J.A., Mosyak L., and Nicholls A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. 48 (2005) 1489-1495
33. Nicholls A., MacCuish N.E., and MacCuish J.D. Variable selection and model validation of 2D and 3D molecular descriptors. J. Comput.-Aided Mol. Des. 18 (2004) 451-474
34. Vinter J.G. Extended electron distributions applied to the molecular mechanics of some intermolecular interactions. J. Comp.-Aided Mol. Des. 8 (1994) 653-668
35. Cheeseright T., Mackey M., Rose S., and Vinter A. Molecular field extrema as descriptors of biological activity: definition and validation. J. Chem. Inf. Model. 46 (2006) 665-676
36. Vinter J.G., and Trollope K.I. Multiconformational composite molecular-potential fields in the analysis of drug-action. 1. Methodology and first evaluation using 5-HT and histamine action as examples. J. Comput.-Aided Mol. Des. 9 (1995) 297-307
37. Schneider G., Neidhart W., Giller T., and Schmid G. "Scaffold-hopping" by topological pharmacophore search: a contribution to virtual screening. Angew. Chem.-Int. Ed. 38 (1999) 2894-2896
38. Cramer R.D., Jilek R.J., Guessregen S., Clark S.J., Wendt B., and Clark R.D. "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. J. Med. Chem. 47 (2004) 6777-6791
39. Nicholls A., and Grant J.A. Molecular shape and electrostatics in the encoding of relevant chemical information. J. Comput.-Aided Mol. Des. 19 (2005) 661-686
40. Barker E.J., Buttar D., Cosgrove D.A., Gardiner E.J., Kitts P., Willett P., and Gillet V.J. Scaffold hopping using clique detection applied to reduced graphs. J. Chem. Inf. Model. 46 (2006) 503-511
41. Molecular Operating Environment, version 2006.06, 2006, Chemical Computing Group Inc., Montreal, Quebec, Canada.
42. Keller P.A., Bowman M., Dang K.H., Garner J., Leach S.P., Smith R., and McCluskey A. Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity. J. Med. Chem. 42 (1999) 2351-2357
43. McCluskey A., Keller P.A., Morgan J., and Garner J. Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as corticotropin releasing hormone type 1 antagonists. Org. Biomol. Chem. 1 (2003) 3353-3361
44. Jilek R.J., and Cramer R.D. Topomers: a validated protocol for their self-consistent generation. J. Chem. Inf. Comp. Sci. 44 (2004) 1221-1227
45. CONCORD was developed by R.S. Pearlman, A. Rusinko, J.M. Skell, R. Baducci, at the University of Texas, Austin, and distributed by Tripos, Inc., 1699 S. Hanley Rd., St. Louis, MO 63144.
46. Cramer R.D., Clark R.D., Patterson D.E., and Ferguson A.M. Bioisosterism as a molecular diversity descriptor: steric fields of single "topomeric" conformers. J. Med. Chem. 39 (1996) 3060-3069
47. Bender A., and Glen R.C. Discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication. J. Chem. Inf. Model. 45 (2005) 1369-1375
48. McGaughey G.B., Sheridan R.P., Bayly C.I., Culberson J.C., Kreatsoulas C., Lindsley S., Maiorov V., Truchon J.F., and Cornell W.D. Comparison of topological, shape, and docking methods in virtual screening. J. Chem. Inf. Model. 47 (2007) 1504-1519
49. A. Nakazato, T. Okubo, D. Nozawa, T. Tamita, L.E.J. Kennis, Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group. Patent 2005, Taisho Pharmaceutical Co. Ltd., WO2005066182.